Omalizumab as a corticosteroidâsparing agent in the treatment of bullous pemphigoid
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15946
Abstract: Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease, characterized by the development of autoantibodies against hemidesmosomal components BP180 and BP230. The mainstay of therapy is topical and systemic corticosteroids (CS) and immunosuppressors.… read more here.
Keywords: bullous pemphigoid; omalizumab corticosteroid; bp180 bp230; pemphigoid ... See more keywords